Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE
Haran, A. M. Jain, Y. Hambrock, T. Murphy, L. R. Cook, A. Brown, L. C. Hoyle, Alex P Sachdeva, Ashwin Ali, S. A. Amos, C. L.
Haran, A. M.
Jain, Y.
Hambrock, T.
Murphy, L. R.
Cook, A.
Brown, L. C.
Hoyle, Alex P
Sachdeva, Ashwin
Ali, S. A.
Amos, C. L.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Haran AM, Jain Y, Hambrock T, Murphy LR, Cook A, Brown LC, et al. Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE. Annals of Oncology. 2022 Sep;33(7):S1161-S2. PubMed PMID: WOS:000866211601616.